Plasma is a better source of tumor-derived circulating cell-free DNA than serum for the detection of EGFR alterations in lung tumor patients

Lung Cancer

Volumn 82, Issue 2, 2013, Pages 373-374

  Vallée, Audrey ^a   Marcq, Marie ^b   Bizieux, Acya ^b   Kouri, Claude El ^c   Lacroix, Hervé ^a   Bennouna, Jaafar ^d   Douillard, Jean Yves ^d   Denis, Marc G ^a  

^a NANTES UNIVERSITY HOSPITAL   (France)

^b La Roche sur Yon Hospital ^*  (France)

^c Centre Catherine de Sienne   (France)

^d Institut de Cancérologie de l'Ouest ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

CELL FREE NUCLEIC ACID; EPIDERMAL GROWTH FACTOR RECEPTOR; NUCLEIC ACID; UNCLASSIFIED DRUG;

BLOOD SAMPLING; CELL FREE SYSTEM; FOLLOW UP; GENE MUTATION; HUMAN; LETTER; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MALIGNANT PLEURA EFFUSION; MUTATION RATE; PLEURA EFFUSION; PRIORITY JOURNAL;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MUTATION; PEPTIDE NUCLEIC ACIDS; PLEURAL EFFUSION, MALIGNANT; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84887017686     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.08.014     Document Type: Letter

References (11)

1. Yeo C.D., Kim J.W., Kim K.H., Ha J.H., Rhee C.K., Kim S.J., et al. Detection and comparison of EGFR mutations in matched tumor tissues, cell blocks, pleural effusions, and sera from patients with NSCLC with malignant pleural effusion, by PNA clamping and direct sequencing. Lung Cancer 2013, 81:207-212.
2. Mandel P., Metais P. Les acides nucléiques du plasma sanguin chez l'homme. C R Seances Soc Biol Fil 1948, 142:241-243.
3. Akca H., Demiray A., Yaren A., Bir F., Koseler A., Iwakawa R., et al. Utility of serum DNA and pyrosequencing for the detection of EGFR mutations in non-small cell lung cancer. Cancer Genet 2013, 206:73-80.
4. Punnoose E.A., Atwal S., Liu W., Raja R., Fine B.M., Hughes B.G.M., et al. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: association with clinical endpoints in a phase II clinical trial of pertuzumab and erlotinib. Clin Cancer Res 2012, 18:2391-2401.
5. Isobe K., Hata Y., Kobayashi K., Hirota N.A.O., Sato K., Sano G.O., et al. Clinical significance of circulating tumor cells and free DNA in non-small cell lung cancer. Anticancer Res 2012, 32:3339-3344.
6. Goto K., Ichinose Y., Ohe Y., Yamamoto N., Negoro S., Nishio K., et al. Epidermal growth factor receptor mutation status in circulating free DNA in serum: from IPASS, a phase III study of gefitinib or carboplatin/paclitaxel in non-small cell lung cancer. J Thorac Oncol 2012, 7:115-121.
7. Schwarzenbach H., Hoon D.S.B., Pantel K. Cell-free nucleic acids as biomarkers in cancer patients. Nat Rev Cancer 2011, 11:426-437.
8. Taniguchi K., Uchida J., Nishino K., Kumagai T., Okuyama T., Okami J., et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 2011, 17:7808-7815.
9. Nakamura T., Sueoka-Aragane N., Iwanaga K., Sato A., Komiya K., Kobayashi N., et al. Application of a highly sensitive detection system for epidermal growth factor receptor mutations in plasma DNA. J Thorac Oncol 2012, 7:1369-1381.
10. Rosell R., Carcereny E., Gervais R., Vergnenegre A., Massuti B., Felip E., et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012, 13:239-246.
11. El Messaoudi S., Rolet F., Mouliere F., Thierry A.R. Circulating cell free DNA: preanalytical considerations. Clin Chim Acta 2013, 424:222-230.